Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma

1

Intrahepatic cholangiocarcinoma (ICC) is an aggressive cancer with poor outcomes, often diagnosed at an unresectable stage.
2

The standard first-line treatment for advanced ICC is the gemcitabine and cisplatin regimen, which has limited effectiveness.
3

A 71-year-old male with initially unresectable ICC underwent conversion therapy using portal vein embolization, surufatinib, sintilimab, and FOLFOX.
4

Post-treatment imaging showed significant tumor reduction and increased future liver remnant, allowing for successful radical resection.
5

The patient achieved 28 months of disease-free survival after surgery, highlighting the potential of multimodal conversion therapy for advanced ICC.

1